Literature DB >> 32982641

Luminal Breast Cancer: The Head of Janus in Breast Oncology.

Oleg Gluz1,2.   

Abstract

Entities:  

Year:  2020        PMID： 32982641      PMCID： PMC7490653          DOI： 10.1159/000509891

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  4 in total

1.  European cancer mortality predictions for the year 2019 with focus on breast cancer.

Authors:  M Malvezzi; G Carioli; P Bertuccio; P Boffetta; F Levi; C La Vecchia; E Negri
Journal:  Ann Oncol       Date:  2019-05-01       Impact factor: 32.976

2.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Authors:  Fatima Cardoso; Laura J van't Veer; Jan Bogaerts; Leen Slaets; Giuseppe Viale; Suzette Delaloge; Jean-Yves Pierga; Etienne Brain; Sylvain Causeret; Mauro DeLorenzi; Annuska M Glas; Vassilis Golfinopoulos; Theodora Goulioti; Susan Knox; Erika Matos; Bart Meulemans; Peter A Neijenhuis; Ulrike Nitz; Rodolfo Passalacqua; Peter Ravdin; Isabel T Rubio; Mahasti Saghatchian; Tineke J Smilde; Christos Sotiriou; Lisette Stork; Carolyn Straehle; Geraldine Thomas; Alastair M Thompson; Jacobus M van der Hoeven; Peter Vuylsteke; René Bernards; Konstantinos Tryfonidis; Emiel Rutgers; Martine Piccart
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

3.  Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

4.  Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Authors:  Ulrike Nitz; Oleg Gluz; Matthias Christgen; Ronald E Kates; Michael Clemens; Wolfram Malter; Benno Nuding; Bahriye Aktas; Sherko Kuemmel; Toralf Reimer; Andrea Stefek; Fatemeh Lorenz-Salehi; Petra Krabisch; Marianne Just; Doris Augustin; Cornelia Liedtke; Calvin Chao; Steven Shak; Rachel Wuerstlein; Hans H Kreipe; Nadia Harbeck
Journal:  Breast Cancer Res Treat       Date:  2017-06-29       Impact factor: 4.872
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.